戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 n the Randomized Aldactone Evaluation Study (RALES).
2 ironolactone initiation after publication of RALES.
3 eased >7-fold (3.0% to 21.3% P<0.0001) after RALES.
4                   Of all prescriptions after RALES, 30.9% were provided to patients not meeting enrol
5 class correlation coefficients were 0.87 for RALE (95% CI: 0.80, 0.92), 0.86 for Brixia (95% CI: 0.76
6 class correlation coefficients were 0.87 for RALE (95% CI: 0.80, 0.92), 0.86 for Brixia (95% CI: 0.76
7 emia, low systolic blood pressure, pulmonary rales above the bases, or an exacerbation of known ische
8                                          The RALE and AI scores had a strong positive correlation in
9 hanical ventilation had significantly higher RALE and AI scores than those with recovery or without t
10 n physical signs are tachypnea, tachycardia, rales, and cyanosis.
11 ical examination (jugular venous distention, rales, and edema) at baseline in the TOPCAT trial (Treat
12 e adjusted mortality risk with all 3 (edema, rales, and jugular venous distension) versus <3 physical
13 as an absence of peripheral edema, pulmonary rales, and jugular venous pressure <6 cm.
14  increased markedly after the publication of RALES, and many treated patients were at risk for hyperk
15 ongestion (jugular venous distention, edema, rales, and third heart sound) with the primary outcome (
16    Initial chest radiographs were scored for RALE, Brixia, and percentage opacification by one of thr
17 tems (radiographic assessment of lung edema [RALE], Brixia, and percentage opacification) in patients
18 ia and worsening renal function were rare in RALES, but laboratory monitoring was frequent.
19 ngham Criteria variables (dyspnea, pulmonary rales, cardiomegaly, interstitial or pulmonary edema on
20 n findings typical of interstitial fibrosis (rales, clubbing, or cyanosis) raised the risk of subsequ
21 r the Randomized Aldactone Evaluation Study (RALES) demonstrated a 30% mortality benefit for treating
22 ly 2000 to June 2001, n=9468) publication of RALES in September 1999.
23 f the Randomized Aldactone Evaluation Study (RALES) in national cohorts of older patients hospitalize
24 confidence interval {CI}, 1.2-4.1]), to have rales on examination (OR, 1.9 [95% CI, 1.0-3.7]), to be
25                                              Rales on initial examination were associated with early
26 Dyspnoea can progress to orthopnoea (with no rales on lung auscultation) accompanied by weakness, fat
27 istory of stroke, clinical heart failure and rales on physical exam.
28 ase, atrial fibrillation, diabetes mellitus, rales, peripheral edema, higher New York Heart Associati
29   We pooled individual patient data from the RALES (Randomized Aldactone Evaluation Study) and EMPHAS
30                        We used data from the RALES (Randomized Aldactone Evaluation Study) in 1,658 p
31 ile jugular venous distension decreased, and rales remained stable.
32 litative assessment of all CXRs based on the RALE score for assessing the severity of lung involvemen
33 bstantial difference in baseline and maximum RALE scores and AI scores had a higher prevalence of dea
34 ion from 0.87 to 0.94 (95% CI 0.90-0.97) for RALE scores and from 0.82 to 0.91 (95% CI 0.87-0.95) for
35 ed for mechanical ventilation) as subjective RALE scores in patients with COVID-19 pneumonia.
36 ) and Radiographic Assessment of Lung Edema (RALE) scores from frontal chest radiographs (CXRs) for p
37 re, and critical, determined by the modified RALE scoring system.
38 ndividual patient level meta-analysis of the RALES (spironolactone) and EMPHASIS-HF (eplerenone) tria
39                                          The RALES study showed that spironolactone, added to convent
40    Clinical follow-up does not adhere to the RALES trial guidelines, resulting in higher complication
41  setting, we analyzed the application of the RALES trial protocol to the care of 104 patients, whom w
42 h spironolactone treatment compared with the RALES trial.
43 pironolactone for HF after prerelease of the RALES trial.
44 n the Randomized Aldactone Evaluation Study (RALES) trial.
45 (Randomized Spironolactone Evaluation Study [RALES] trial), we noted a marked increase in widespread
46  were heard over the anterior neck, while no rales were audible over any part of the chest.